20th Apr 2026 18:29
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
----------
Great Southern Copper PLC - Chile-focused copper, gold and silver explorer - Begins scout reverse circulation drilling at the Piedras Blancas prospect located on the western margin of the La Colorada lithocap, in the Especularita project. Chief Executive Officer Sam Garrett says: "An initial three scout RC holes are planned, which will test a window of outcropping porphyry-style alteration enclosed by gravels and scree. The alteration is characteristic of the phyllic zone of porphyry copper systems with pervasive silica-sericite-pyrite overprinted by stockworks of pyrite and quartz-pyrite fracture veins. The surface geology is highly oxidised and leached, so we want to get below the oxide zone and confirm what's there and use that information to potentially vector toward the potassic copper-rich core of the porphyry system."
----------
Metir PLC - York, England-based company focused on water testing services - Appoints three new international distributors through its Modern Water subsidiary. In the Kingdom of Saudi Arabia and Bahrain, Ali Salman Al Sinan has been appointed as an authorised distributor. The distributor will initially supply Modern Water's Microtox LX and FX instruments. In Malaysia, Greenson Technology Sdn. Bhd has been appointed as an authorised distributor for Microtox products in Malaysia, Indonesia and Brunei. In Senegal, SENTECH has been appointed as an authorised distributor for Microtox products. Additionally, Metir is in negotiations and close to appointing distributors in both the UAE and Egypt to supply Modern Water's Microtox LX and FX instruments.
----------
Cellbxhealth PLC - Guildford, England-based liquid biopsy company, formerly called Angle PLC - Announces a research collaboration with The Royal Marsden NHS Foundation Trust. The parties will jointly undertake a translational clinical study in 200 patients with advanced non-small cell lung cancer. The prospective, single timepoint study will be embedded within an existing study in which patients are undergoing molecular testing of ctDNA from blood. Secondary objectives include assessing CTC consistency with tumor tissue profiling and evaluating whether the combined approach increases overall detection of clinically relevant genomic mutations.
----------
Reabold Resources PLC - London-based oil and gas investment company - Notes the Telegraph article from April 19. Says "the significant onshore natural gas resource at the West Newton site in Yorkshire has and will continue to be progressed for the benefit of UK energy security, which is particularly important at this time of significant geopolitical uncertainty." Adds that it will continue to ensure "the optimal development pathway for West Newton is achieved." Reabold also says it is exploring the potential to deploy a small-scale power generation facility at the West Newton A well site to mine bitcoin from initial flows of gas following the upcoming well workover. Says this will demonstrate the ability to use West Newton gas to fuel datacenter developments that will be crucial to the future UK economy.
----------
Gana Media Group PLC - London-based mobile gaming content provider - Wholly-owned Mexican media content subsidiary Estadio Deportes enters into a boxing digital broadcasting rights agreement with Izquierdazo Boxeo, a leading Mexican boxing promoter. "This collaboration aims to strengthen the promotion and visibility of boxing in Mexico, allowing Estadio Deportes to broadcast, across its various digital platforms, at least one event per month, in accordance with the regular schedule of events organized by Izquierdazo Boxeo," Gana says.
----------
Helix Exploration PLC - London-based helium exploration and development company advancing the Rudyard helium project in northern Montana - Has been selected by the Renaissance Philanthropy's Chimaera Fund to participate in the Air Force Geologic Hydrogen Energy Resilience Initiative. The demonstration programme is assessing whether geologic hydrogen can strengthen energy resilience at critical air force bases. Helix was selected on the basis of its active helium exploration programme in north-central Montana. "As a core partner, Helix will work alongside the Chimaera Fund contributing subsurface measurements, drilling cost data, mineralogical and geochemical analysis, and well infrastructure data from active field operations near Malmstrom AFB. The results of the programme will inform a techno-economic assessment of geologic hydrogen potential near targeted installations," company says.
----------
Rome Resources PLC - mineral explorer with tin project in Democratic Republic of the Congo - Conditionally raises GBP1.2 million gross by way of a direct subscription with existing shareholders for a total of 400 million shares at an issue price of 0.30 pence. The issue price represents a discount of approximately 8.6% to the five-day volume-weighted average price. Proceeds will be used to continue drilling at its Kalayi project to provide further resource expansion beyond the next planned mineral resource estimate update; drill the two high-graded copper and tin targets at Mont Agoma; and conduct an airborne geophysical survey in order to assess further exploration targets within the remit of Rome Resources' licences.
----------
Genflow Biosciences PLC - London-based biotechnology firm - Enters into a strategic technology collaboration with Acuitas Therapeutics, a leader in lipid nanoparticle delivery systems whose technology underpins mRNA therapeutic programmes. Under the agreement, Genflow will provide its proprietary SIRT6 mRNA payload to Acuitas, which will formulate the payload using its proprietary LNP platform. The resulting formulations will be returned to Genflow for use in preclinical evaluation studies. The collaboration is fully funded by Acuitas. Genflow says: "The board considers this collaboration to represent a material step forward in the advancement of the company's SIRT6 platform. Acuitas' LNP technology is among the most clinically and commercially validated delivery platforms in the mRNA therapeutics industry, and the Company's ability to access this capability on a fully funded basis reflects the external confidence in Genflow's proprietary science. The collaboration will enable Genflow to evaluate the integration of LNP-based delivery with its SIRT6 mRNA payload across a newly initiated development programme, with the objective of generating preclinical data to support future clinical and commercial development decisions."
----------
By Aidan Lane, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Great Sth CoppReabold ResourcesCellbxhealthHelix ExplorationGenflow BiosciRome Resources PLCGana MediaMetir Plc